TO
Tim Opler

Tim Opler

Things Tim Says on Podcasts

Managing Director in Stifel's Global Healthcare Group who advises biotech and pharma companies on M&A, licensing and financings. Co-founded the advisory firm Torreya, which Stifel acquired in 2023, and has completed more than 150 transactions. Writes Stifel's Biopharma Market Updates and earlier worked at Credit Suisse First Boston and as a finance professor at The Ohio State University. Co-hosts Biotech Hangout with Daphne Zohar, Josh Schimmer, Brad Loncar and others. Appears as a guest on The BioCentury Show, Odd Lots and Beyond Biotech from Labiotech.

Where to Find Them

Tim Opler hosts Biotech Hangout . They have also been a guest on BiotechTV - News (2 times) , The BioCentury Show , Odd Lots and Beyond Biotech - the podcast from Labiotech .

Recently: “Episode 204 - November 20, 2026” on Biotech Hangout (November 2026); “Stifel's Tim Opler on the state of biotech” on BiotechTV - News (November 2026); “Episode 191 - July 31, 2026” on Biotech Hangout (August 2026); “Episode 170 - January 23, 2026” on Biotech Hangout (January 2026); “Top 5 trends that will drive biopharma in the next decade with Tim Opler” on Beyond Biotech - the podcast from Labiotech (January 2026); “Episode 147 - July 11, 2025” on Biotech Hangout (July 2025).

What They Said

“The XBI is down a full 10 percentage points since I started to write that report. I heard pretty negative sentiment. The general sense, from a biotech investor, was that these AI companies need way, way too much money, the US government needs way, way too much money. We saw one AI company with an investment grade go out and raise fixed income money this week at an 8% coupon.” — Tim Opler, Biotech Hangout

Opler had just published an upbeat State of Biotech report, then watched the biotech index slide. He relays why investors think AI's appetite for capital is crowding out biotech. He calls himself an optimist and expects the slump to pass.

Biotech Hangout · 2026-11-20 Permalink → Listen →
Biotech Hangout Around 01:07 into the episode
Graig Suvannavejh

…So with that in mind, that's just a high-level view. I'm going to turn things over to Tim, who again puts out a great periodic report called The State of Biotech. His last report came out, I think, last Friday. So I'm going to pass it over to him on some of his insights. So Tim Opler to you.

Tim Opler

Greg, thank you very much. And the report I put out, I think Daphne put a link to it on X. So if you know anyone wants to access it, you can. It's a kind of a long report that really just sort of goes through the whole market. It's very interesting. Bruce Booth also put out a very nice report, which I highly recommend that kind of goes through the whole market as well. And what's nice is the reports are, of course, different. We all have our own perspective. I'm known as being the Oplarbest. So I'm a very optimistic person. And so occasionally I'll go negative on the market. But in that report, I was very upbeat about where biotech is going to go. So that teaches me, right? So since I started to write that report, the XBI is down a full 10 percentage point. So that's actually quite a significant drop in, what, three, four weeks. And so I was talking to some relatively knowledgeable investors in the market yesterday, like what is going on. And I wouldn't say that I heard panic, but I heard like pretty negative sentiment. And, you know, that's obviously not what's going through my head. So like what's happening in the market now? And, you know, we saw the…

Graig Suvannavejh

Thanks, Tim, for that. Maybe just to throw it out there to our group, how are you all thinking about 2027, especially as we come down to the end of 2026? Do we think that it's going to be as robust of an IPO market and a biotech performance perspective? I could see M ⁇ A at a good pace. In fact, it…

Matt Gline

For me, and you would ask me to make a comment about the Anthropic IPO too. I think the main thing that I find difficult to reason through is there's like a whole bunch of biotech specific dynamics. I thought Tim did a really nice job of laying it out. It feels like we are all strapped to a…

Brian Skorney

Yeah, let me just add to what Matt's saying, because I think he's spot on. So I did a, I was thinking the same themes and I did a quick AI search. So take it with a grain of salt. But I said, what percent of the total U.S. stock market publicly traded companies is represented by the companies that…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.
“Historically, if a rumor appears that company X has interest from company Y, there's a 14% chance that transaction actually happens. If it appears in the Wall Street Journal, there's a two in three chance. 50% if it's in the Financial Times. If it's in Bloomberg, it's a 37% chance.” — Tim Opler, Biotech Hangout

The group was discussing a Bloomberg report that Sanofi was weighing a bid for Insmed. Opler cites his own study of about a hundred M&A rumors from recent years to explain why he's skeptical of this one.

Biotech Hangout · 2026-11-20 Permalink → Listen →
Biotech Hangout Around 25:32 into the episode
Tim Opler

on that?

Matt Gline

Sure.

Tim Opler

On Instmed. So back in February, I published a little piece called Cheat Talk: Fake News and Biotech M ⁇ A Rumors. And I looked at 103 rumors that had appeared in the news between June 2021 and January 2026. So if a rumor appears that says XYZ company has interest from ABC company, historically, there's a 14% chance that that transaction actually happens. And if the rumor appears, any rumor appears about an MA in the Wall Street Journal, there's a two in three chance that it will happen. 50% chance if it's in the Financial Times. And if it's in Bloomberg, it's a 37% chance. So this is just looking at the rumor itself, a particularly weak rumor, because it says that Sanofi is considering buying Instmed. And it appeared in Bloomberg, which has a record of, let's just say, probably a lower threshold of publishing rumors. So I'm a skeptic on this one. I would also note that Paul Hudson is on the board of InSMED. And while Will Lewis was indeed a former CIA officer, one of my friends saw him just a week ago, and he looked incredibly relaxed and happy. Not a guy that…

Graig Suvannavejh

I'll leave it to Tim to do that analysis, which is incredible. Thank you for those statistics. Yeah, we will see what transpires here. We published a note this week since, again, I cover InSMED. I didn't think that this deal was going to go down at least immediately, but I do think that given the…

Tim Opler

Yeah, well, I mean, look, it's notable that they mentioned the upfront, which I think we want to see more of. But yeah, first, I think the industry should, you know, pitch in and buy a big collective effort to get a Christmas present to Lilly this year because they really, I think I read that there…

Graig Suvannavejh

biparotropic double-barreled antibody for the treatment of myeloproliferative neoplasms. These are rare blood cancers like myelofibrosis, thrombocythemia. These are currently treated with blood transfusions or Insights Jack inhibitor. Lilly also has other programs in these spaces. So they're…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.

Collections They Appear In